
Speaker "Stefan Lukianov" Details Back


-
Name
Stefan Lukianov
-
Company
Salve Therapeutics
-
Designation
CEO
Topic
AI biologic design
Abstract
Current gene therapies are mostly limited to plasmid-based and Adeno-associated virus variants with inefficient response rates and limited use. Better viral delivery methods would expand the available pharmacopeia to produce precision medicines for intractable and incurable genetic diseases. We are building VirCAD© (Virus Computer-Aided Design), an HPC-powered, cloud-accessible, AI/ML-capable bioCAD platform to mine, design, model and test new viral drugs for improved cell and gene therapies, vaccines, oncolytics, antibiotics and other categories. These modalities will treat the many inherited and acquired genetic disorders afflicting patients due to their therapeutic specificity, efficiency, and customizability.
Profile
Stefan N. Lukianov, MS, AM, is the founder/CEO of Salve Therapeutics and has trained at UMaine, Pitt, Harvard and Hopkins.